Bio-Rad Labs (BIO) Tops Q2 EPS by 39c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Bio-Rad Reports Second-Quarter 2020 Financial Results
July 30, 2020 4:15 PM EDTHERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2020.
Second-quarter 2020 net sales were $536.9 million, a decrease of 6.2 percent compared to $572.6 million reported for the second quarter of 2019. On a currency-neutral basis, quarterly sales decreased 4.4 percent compared to the same period in 2019. Second-quarter gross margin was 54.6 percent compared to 53.7 percent during the second quarter in 2019.
The COVID-19 pandemic created some opportunities for our products while also negatively impacting some of our business operations... More
